Granuloma annulare: modern concepts of pathogenesis and pathogenetically based therapy (literature review)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Granuloma annulare is a chronic, benign, non-infectious skin disorder that causes ring-shaped papules, most commonly on the hands and feet. The condition is considered rare, according to some data, it affects less than 0.04% of the population. However, in recent years there has been an increase in the incidence of dermatosis, which is associated with the high prevalence of infectious diseases, including infections caused by the SARS-CoV-2 coronavirus. The pathogenesis of granuloma annulare has not been fully deciphered; nevertheless, comparative analysis of a wide range of biomarkers in biopsies of affected skin has shown differences in the expression of genes involved in regulation of innate immunity, Th1 and Th2 lymphocytes, and Janus kinases. Associations of granuloma annulare with endocrine, immune, and autoimmune diseases, malignant neoplasms, as well as the triggering role of infections and vaccinations, are subjects of discussion, despite advances in understanding the molecular mechanisms of disease development.

The treatment of granuloma annulare presents quite complex challenge. Topical corticosteroids can be effective in localized forms of the disease. Calcineurin inhibitors can be used in combination with them. For disseminated forms of the dermatosis, narrowband medium wave ultraviolet therapy at 311 nm, PUVA, and 308 nm excimer ultraviolet light therapy are prescribed. There are descriptions of the effectiveness of antibacterial drugs.

Currently, TNF-α inhibitors, JAK inhibitors and IL-23 inhibitors are proposed as targeted therapy for granuloma annulare. The basis for this recommendation is the latest information about the pathogenesis of granuloma annulare.

The presented literature review systematizes modern concepts of molecular and cellular mechanisms of granuloma annulare development, infectious and non-infectious triggers of inflammation, the role of endocrine, immune and oncological pathology as predisposing factors. Significant importance is given to the analysis of treatment methods of the disease.

About the authors

Chanilka A. Pahalage

Saint-Petersburg State University; Leningrad Regional Center for Specialized Types of Medical Care

Author for correspondence.
Email: chanilka92@hotmail.com
ORCID iD: 0000-0002-1713-4123
SPIN-code: 2828-8975
Russian Federation, Saint Petersburg; Saint Petersburg

Irina O. Smirnova

Saint-Petersburg State University; City Dermatological and Venereological Dispensary

Email: driosmirnova@yandex.ru
ORCID iD: 0000-0001-8584-615X
SPIN-code: 5518-6453

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Saint Petersburg; Saint Petersburg

Polina D. Ptashnikova

Saint-Petersburg State University

Email: enternita7@yandex.ru
ORCID iD: 0000-0003-4699-1746
SPIN-code: 8715-3940
Russian Federation, Saint Petersburg

References

  1. Joshi TP, Tschen J. Apremilast for the treatment of generalized granuloma annulare: A case series of 8 patients. JAAD Case Rep. 2023;38:59–60. doi: 10.1016/j.jdcr.2023.06.011 EDN: FVTVUA
  2. Fox TC. Ringed eruption of the fingers. Br J Dermatol. 1895;7:91.
  3. Radcliffe-Crocker H. Granuloma annulare. Br J Dermatol. 1902;14:1–9.
  4. Little EG. Granuloma annulare. Proc R Soc Med. 1908;1(Dermatol Sect):33–34.
  5. Schmieder SJ, Harper CD, Schmieder GJ. Granuloma annulare. 2023 Jun 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
  6. Garg S, Baveja S. Generalized granuloma annulare treated with monthly rifampicin, ofloxacin, and minocycline combination therapy. Indian J Dermatol. 2013;58(3):197–199. doi: 10.4103/0019-5154.110828
  7. Corrà A, Quintarelli L, Verdelli A, et al. Granulomatous dermatitis and systemic disease: An association to consider. Biomed Res Int. 2020;2020:3281380. doi: 10.1155/2020/3281380
  8. Bari A, Namdev V, Virani BR, et al. Inflammatory granulomatous corneal disease: Ocular granuloma annulare. Cureus. 2024;16(6):e62582. doi: 10.7759/cureus.62582 EDN: DRNUCA
  9. Cojocaru A, Dorobanţu AM, Bălăceanu B, et al. A Rare association of disseminated granuloma annulare with recurrent uveitis. Cureus. 2024;16(2):e53570. doi: 10.7759/cureus.53570 EDN: BOEIID
  10. Chatterjee D, Kaur M, Punia RP, et al. Evaluating the unusual histological aspects of granuloma annulare: A study of 30 cases. Indian Dermatol Online J. 2018;9(6):409–413. doi: 10.4103/idoj.IDOJ_75_18
  11. Piette EW, Rosenbach M. Granuloma annulare: Clinical and histologic variants, epidemiology and genetics. J Am Acad Dermatol. 2016;75(3):457–465. doi: 10.1016/j.jaad.2015.03.054
  12. Barbieri JS, Rosenbach M, Rodriguez O, Margolis DJ. Association of granuloma annulare with type 2 diabetes, hyperlipidemia, autoimmune disorders, and hematologic malignant neoplasms. JAMA Dermatol. 2021;157(7):817–823. doi: 10.1001/jamadermatol.2021.1805 EDN: XFHPRD
  13. Guglielmo A, Virdi A, Misciali C, et al. Generalized granuloma annulare-like eruption secondary to acute Epstein-Barr virus infection. Int J Dermatol. 2021;60(3):e110–e112. doi: 10.1111/ijd.15274 EDN: QLSKUB
  14. Mann E, Maruthi R, Friedland MH, et al. Case of post-herpetic, isotopic granuloma annulare (GA), followed by generalized GA. J Dermatol. 2019;46(12):e476–e477. doi: 10.1111/1346-8138.15088
  15. García-Gil MF, Monte Serrano J, García García M, et al. Granuloma annulare triggered by SARS-CoV-2 infection: The first reported case. J Dermatol. 2021;48(1):e1–e2. doi: 10.1111/1346-8138.15594 EDN: QBHNCU
  16. Lee EC, Steffen CA, Carroz ME, et al. Granuloma annulare and possible relation to purified protein derivative administration: A case report. J Med Case Rep. 2024;18(1):299. doi: 10.1186/s13256-024-04598-w EDN: UTPNTR
  17. Mărculescu F, PătraȘcu V, Tutunaru CV, Ochiana L. Granuloma annulare, a possible paradoxical reaction of the adalimumab treatment in a severe case of psoriasis vulgaris. Curr Health Sci J. 2020;46(2):203–206. doi: 10.12865/CHSJ.46.02.16
  18. Fässler M, Schlapbach C. Granuloma annulare arising under systemic psoriasis therapy successfully treated with adalimumab. JAAD Case Rep. 2020;6(9):832–834. doi: 10.1016/j.jdcr.2020.07.013 EDN: VDHPEH
  19. Matsuo M, Niwa H, Iwata H. Papular umbilicated granuloma annulare in a patient with systemic lupus erythematosus. Cureus. 2023;15(10):e47600. doi: 10.7759/cureus.47600 EDN: LQKSHT
  20. Leasure AC, Damsky W, Cohen JM. Comorbidities associated with granuloma annulare: A case-control study in the all of us research program. J Am Acad Dermatol. 2022;87(1):197–199. doi: 10.1016/j.jaad.2021.07.033 EDN: ASHTRA
  21. Min MS, Wu J, He H, et al. Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. J Am Acad Dermatol. 2020;83(1):63–70. doi: 10.1016/j.jaad.2019.12.028
  22. Wang A, Rahman NT, McGeary MK, et al. Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. J Allergy Clin Immunol. 2021;147(5):1795–1809. doi: 10.1016/j.jaci.2020.10.012 EDN: BJDWJE
  23. Wang J, Khachemoune A. Granuloma annulare: A focused review of therapeutic options. Am J Clin Dermatol. 2018;19(3):333–344. doi: 10.1007/s40257-017-0334-5 EDN: TJNPBD
  24. Min MS, Lebwohl M. Treatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study. J Am Acad Dermatol. 2016;74(1):127–133. doi: 10.1016/j.jaad.2015.09.015
  25. Zhguleva AS, Zementova MS, Selkov SA, Sokolov DI. M1/M2 macrophages: Origin, phenotype, methods of production, interaction with natural killer cells and trophoblast. Medical Immunology. 2024;26(3):425–448. doi: 10.15789/1563-0625-MMO-2877 EDN: LYFSSE
  26. Grunewald J, Kaiser Y, Ostadkarampour M, et al. T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur Respir J. 2016;47(3):898–909. doi: 10.1183/13993003.01209-2015
  27. Friedman SJ, Winkelmann RK. Familial granuloma annulare: Report of two cases and review of the literature. J Am Acad Dermatol. 1987;16(3 Pt 1):600–605. doi: 10.1016/s0190-9622(87)70080-2
  28. Agrawal P, Pursnani N, Jose R, Farooqui M. Granuloma annulare: A rare dermatological manifestation of diabetes mellitus. J Family Med Prim Care. 2019;8(10):3419–3421. doi: 10.4103/jfmpc.jfmpc_616_19
  29. Al Ameer MA, Al-Natour SH, Alsahaf HA, et al. Eruptive granuloma annulare in an elderly man with diabetes. Cureus. 2022;14(1):e21242. doi: 10.7759/cureus.21242 EDN: LTZVKD
  30. Stefaniak AA, Szepietowski JC, Baran W. Unilateral papular granuloma annulare in a type I diabetic child: A case report and literature review. Postepy Dermatol Alergol. 2022;39(3):637–639. doi: 10.5114/ada.2021.107547 EDN: KHMZIY
  31. Nordmann TM, Kim JR, Dummer R, Anzengruber F. A monocentric, retrospective analysis of 61 patients with generalized granuloma annulare. Dermatology. 2020;236(4):369–374. doi: 10.1159/000507247 EDN: DBKRAI
  32. Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: A translational perspective. Expert Rev Endocrinol Metab. 2010;5(1):19–28. doi: 10.1586/eem.09.44
  33. Jandali B, Uthman I, Abbas O. Interstitial granulomatous dermatitis associated with systemic lupus erythematosus: Case report and review of the literature. Lupus. 2016;25(2):209–213. doi: 10.1177/0961203315604908
  34. Wang H, Wang Y, Zheng Z, Cui Y. Generalized granuloma annulare associated with Sjogren’s syndrome: A case report. Clin Cosmet Investig Dermatol. 2023;16:453–456. doi: 10.2147/CCID.S399782
  35. Sumikawa Y, Ansai S, Kimura T, et al. Interstitial type granuloma annulare associated with Sjögren’s syndrome. J Dermatol. 2010;37(5):493–495. doi: 10.1111/j.1346-8138.2010.00865.x
  36. Polineni SP, Lawyer S. Generalized granuloma annulare associated with essential thrombocythemia. Clin Case Rep. 2020;8(6):1065–1068. doi: 10.1002/ccr3.2812 EDN: YBPKGW
  37. Elshimy G, Raj R. PSAT353 Can generalized granuloma annulare occur in patients with Graves’ disease? J Endocr Soc. 2022;6(Suppl 1):A837. doi: 10.1210/jendso/bvac150.1730
  38. Tabata MM, Novoa RA, Martires KJ. Paraneoplastic granulomatous dermatitis in a patient with Hodgkin’s disease: A diagnostic pitfall. BMJ Case Rep. 2018;2018:bcr2018224961. doi: 10.1136/bcr-2018-224961
  39. Li A, Hogan DJ, Sanusi ID, Smoller BR. Granuloma annulare and malignant neoplasms. Am J Dermatopathol. 2003;25(2):113–116. doi: 10.1097/00000372-200304000-00004
  40. Harman RR. Hodgkin’s disease, seminoma of testicle and widespread granuloma annulare. Br J Dermatol. 1977;97(Suppl S15):50–51. doi: 10.1111/j.1365-2133.1977.tb14325.x
  41. Bagci B, Karakas C, Kaur H, Smoller BR. Histopathologic aspects of malignancy-associated granuloma annulare: A single institution experience. Dermatopathology (Basel). 2023;10(1):95–103. doi: 10.3390/dermatopathology10010015 EDN: QXWXQO
  42. Saber M, Khalili Tembi RS, Asilian A. Generalized granuloma annulare in a case of breast cancer: A case report and review of the literature. Clin Case Rep. 2021;9(10):e04980. doi: 10.1002/ccr3.4980 EDN: ORNWYJ
  43. Cho SI, Yu DA, Lee JH, et al. Paraneoplastic generalized granuloma annulare in a patient with hepatocellular carcinoma. Ann Dermatol. 2018;30(4):503–504. doi: 10.5021/ad.2018.30.4.503
  44. Barbieri JS, Rosenbach M, Rodriguez O, Margolis DJ. Granuloma annulare is not associated with solid-organ malignancies: A cohort study. J Am Acad Dermatol. 2022;86(6):1352–1354. doi: 10.1016/j.jaad.2021.04.098
  45. Gabaldón VH, Haro-González-Vico V. Lack of an association between generalized granuloma annulare and malignancy: A case-control study. J Am Acad Dermatol. 2019;80(6):1799–1800. doi: 10.1016/j.jaad.2019.02.056
  46. Garate D, Thang CJ, Damsky W, et al. Granuloma annulare is associated with an increased risk of hematologic malignancies: A multicenter cohort study using TriNetX. J Am Acad Dermatol. 2024;90(4):862–864. doi: 10.1016/j.jaad.2023.12.028 EDN: QRAIKH
  47. Wu J, Kwong BY, Martires KJ, et al. Granuloma annulare associated with immune checkpoint inhibitors. J Eur Acad Dermatol Venereol. 2018;32(4):e124–e126. doi: 10.1111/jdv.14617
  48. Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: Onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5:421–431. doi: 10.1586/eci.09.18
  49. Voulgari PV, Markatseli TE, Exarchou SA, et al. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67:567–570. doi: 10.1136/ard.2007.075663
  50. Bonomo L, Ghoneim S, Levitt J. A case of granuloma annulare associated with secukinumab use. Case Rep Dermatol Med. 2017;2017:5918708. doi: 10.1155/2017/5918708
  51. Clark ML, Tobin CA, Sutton A, Missall TA. Granuloma annulare in the setting of secukinumab. Case Rep Dermatol Med. 2018;2018:5175319. doi: 10.1155/2018/5175319
  52. Phelps-Polirer K, Alkhatib BL, Davis C. Generalized granuloma annulare associated with dupilumab therapy. Cureus. 2022;14(7):e27439. doi: 10.7759/cureus.27439 EDN: PTXJQE
  53. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: Adversaries and collaborators. Ann N Y Acad Sci. 2010;1183:211–221. doi: 10.1111/j.1749-6632.2009.05133.x
  54. Kapetanovic I, Bosic M, Lekic B, Zivanovic D. Generalized perforating granuloma annulare associated with latent tuberculosis successfully treated with isoniazid: case report and review. Dermatol Online J. 2023;29(5). doi: 10.5070/D329562404 EDN: PBVEJI
  55. Akay BN, Atak MF, Kirmizi A, Farabi B. Granuloma annulare mimicking eruptive dermatofibroma in an HIV-positive male: A challenge with distinct dermatoscopic findings. Dermatol Ther. 2020;33(3):e13375. doi: 10.1111/dth.13375 EDN: KQUHXX
  56. Al Ali A, Alkhodair R, Thuraisingam T, et al. Multiple granuloma annulare lesions presenting simultaneously with herpes zoster infection: Wolf’s isotopic response. JAAD Case Rep. 2018;4(7):631–632. doi: 10.1016/j.jdcr.2018.03.006
  57. García-Gil MF, Álvarez-Salafranca M, Martínez García A, Ara-Martín M. Generalized granuloma annulare after pneumococcal vaccination. An Bras Dermatol. 2021;96(1):59–63. doi: 10.1016/j.abd.2020.05.009 EDN: AOHXDZ
  58. Youh J, Yamaguchi Y, Shimano M, Hotta M. A case of generalized granuloma annulare induced by intravesical bacillus calmette-guerin immunotherapy. Indian J Dermatol. 2023;68(5):590. doi: 10.4103/ijd.ijd_751_23
  59. Nguyen TH, Gabros S, Friefeld S, et al. Generalized granuloma annulare after COVID-19 vaccination. JAAD Case Rep. 2022;25:18–21. doi: 10.1016/j.jdcr.2022.05.003 EDN: VKVSUG
  60. Emre S, Unal E, Celik B, Sungu N. The case of granuloma annulare associated with SARS-CoV-2 infection. Dermatol Ther. 2022;35(5):e15369. doi: 10.1111/dth.15369 EDN: WDAGQD
  61. Kaur L, Chakraborty D, Dayal S, et al. Subcutaneous granuloma annulare in an atypical age group in immediate post-Covid-19 phase. Dermatol Pract Concept. 2022;12(4):e2022156. doi: 10.5826/dpc.1204a156
  62. Monte-Serrano J, García-Gil MF, García-García M, et al. Granuloma annulare triggered by SARS-CoV-2 infection: Immunohistochemical staining. Dermatol Ther. 2021;34(3):e14897. doi: 10.1111/dth.14897 EDN: WZZKFB
  63. Tahir M, Bodies BF, Shalin S, et al. Dermal granuloma annulare after SARS-CoV-2 vaccination: A rare complication. Cureus. 2024;16(1):e52174. doi: 10.7759/cureus.52174 EDN: WIJFRM
  64. Russo D, Accarino R, Varricchio S, et al. Granuloma annulare after SARS-CoV-2 vaccination: A case report and a literature review. Pathol Res Pract. 2023;242:154300. doi: 10.1016/j.prp.2022.154300 EDN: SZTWEY
  65. Esfandiari N, Benson P, Morley K. Wolf’s isotopic response: A case of dermatomal granuloma annulare after COVID-19 vaccination. JEADV Clin Pract. 2022:10.1002/jvc2.90. doi: 10.1002/jvc2.90
  66. Abrusci V, Weiss E, Planas G. Familial generalized perforating granuloma annulare. Int J Dermatol. 1988;27(2):126–127. doi: 10.1111/j.1365-4362.1988.tb01292.x
  67. Knoell KA. Efficacy of adalimumab in the treatment of generalized granuloma annulare in monozygotic twins carrying the 8.1 ancestral haplotype. Arch Dermatol. 2009;145(5):610–611. doi: 10.1001/archdermatol.2009.92
  68. Vazquez-Lopez F, Pereiro M, Manjon Haces JA, et al. Localized granuloma annulare and autoimmune thyroiditis in adult women: A case-control study. J Am Acad Dermatol. 2003;48(4):517–520. doi: 10.1067/mjd.2003.104
  69. RODVK [Internet]. Ring-shaped granuloma: Clinical guidelines. (In Russ.) Available from: https://diseases.medelement.com/disease/кольцевидная-гранулема-рекомендации-рф/15228?ysclid=m7d49u4qy3100162510 Accessed: 15 Jan 2025.
  70. Visconti MJ, Ashack KA, Ashack RJ. Granuloma annulare: Strengthening potential associations and pentoxifylline as a therapeutic option. J Dermatol Treat. 2021;32(4):381–382. doi: 10.1080/09546634.2019.1662366
  71. Lopez-Navarro N, Castillo R, Gallardo MA, et al. Successful treatment of perforating granuloma annulare with 0.1% tacrolimus ointment. J Dermatolog Treat. 2008;19(6):376–377. doi: 10.1080/09546630802132650
  72. Bronfenbrener R, Ragi J, Milgraum S. Granuloma annulare treated with excimer laser. J Clin Aesthet Dermatol. 2012;5(11):43–45.
  73. Muylaert BP, Almada R, Vasconcelos RC. Granuloma annulare treated with narrowband UVB phototherapy. An Bras Dermatol. 2017;92(5 Suppl 1):82–84. doi: 10.1590/abd1806-4841.20174994
  74. Hrin ML, Bashyam AM, Feldman SR, Huang WW. Oral dapsone for the treatment of generalized granuloma annulare: A retrospective case series. J Am Acad Dermatol. 2022;86(4):911–914. doi: 10.1016/j.jaad.2021.03.045 EDN: TMDXSR
  75. Rubin CB, Rosenbach M. Granuloma annulare: A retrospective series of 133 patients. Cutis. 2019;103(2):102–106.
  76. Mostafa N, Phan K, Smith SD. Antimalarial therapy for granuloma annulare: A systematic review. J Dermatolog Treat. 2022;33(2):1202–1203. doi: 10.1080/09546634.2020.1801973 EDN: OYRHUU
  77. McPhie ML, Swales WC, Gooderham MJ. Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report. SAGE Open Med Case Rep. 2021;9:2050313X211039477. doi: 10.1177/2050313X211039477 EDN: RZUEJD
  78. Damsky W, Thakral D, McGeary MK, et al. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–621. doi: 10.1016/j.jaad.2019.05.098 EDN: GRRSIB
  79. Damsky W, King BA. Treatment of granuloma annulare with tofacitinib 2% ointment. JAAD Case Rep. 2019;6(1):69–71. doi: 10.1016/j.jdcr.2019.10.016
  80. Durgin JS, Shields BE, Rosenbach M. Generalized granuloma annulare: A widespread response to limited application of compounded 2% topical tofacitinib. JAAD Case Rep. 2020;6(10):1113–1115. doi: 10.1016/j.jdcr.2020.07.054
  81. Bosch-Amate X, Serra-García L, Alamon-Reig F, et al. Treatment of granuloma annulare with tofacitinib. Australas J Dermatol. 2022;63(3):400–403. doi: 10.1111/ajd.13875 EDN: BHUNOP
  82. De Greef A, Benjelloun G, Harkemanne E, Baeck M. Successful treatment of disseminated granuloma annulare with upadacitinib. Dermatol Ther (Heidelb). 2024;14(3):813–817. doi: 10.1007/s13555-024-01117-z EDN: KGUFEW
  83. Slater KN, Valk B, Kartono F. A case of generalized granuloma annulare treated with upadacitinib. JAAD Case Rep. 2023;34:12–14. doi: 10.1016/j.jdcr.2023.01.027 EDN: KZKVZM
  84. Zheng J, Sharma S, Wassell K, et al. Letter to the editor: Effective treatment of disseminated granuloma annulare with upadacitinib. JAAD Case Rep. 2023;44:98–100. doi: 10.1016/j.jdcr.2023.11.024 EDN: AOEBAS
  85. Coican A, Meckley A, Sagasser N, et al. Successful treatment of refractory generalized granuloma annulare with upadacitinib. Case Rep Dermatol Med. 2024;2024(1):8859178. doi: 10.1155/2024/8859178 EDN: FOPTVO
  86. Yan TM, Zhang H, Wu XY, Zhang ZY. Successful treatment of generalized granuloma annulare with baricitinib. J Eur Acad Dermatol Venereol. 2022;36(7):e500–e502. doi: 10.1111/jdv.18031 EDN: VNRCJH
  87. Jadoul A, Huygen L, Leemans G, et al. JAK1/2 pathway-specific treatment of disseminated granuloma annulare with baricitinib. J Eur Acad Dermatol Venereol. 2023 Mar 28. doi: 10.1111/jdv.19073 EDN: XOBWQO
  88. Kim D, Kang HY. Rapid improvement of refractory generalized granuloma annulare with the Janus kinase inhibitor baricitinib in two patients. Clin Exp Dermatol. 2023;48(4):375–376. doi: 10.1093/ced/llac110 EDN: NFIIYD
  89. Piontkowski AJ, Wei N, Mumtaz A, Gulati N. Ruxolitinib cream for the treatment of granuloma annulare. JAAD Case Rep. 2024;50:62–64. doi: 10.1016/j.jdcr.2024.05.030 EDN: SLHGSO
  90. Sondermann W, Hadaschik E, Specker C. Successful therapy of disseminated patch-type granuloma annulare with upadacitinib in a patient with rheumatoid arthritis. Dermatol Ther. 2022;35(1):e15211. doi: 10.1111/dth.15211 EDN: IHTSVX
  91. Shirley M. Dupilumab: First global approval. Drugs. 2017;77(10):1115–1121. doi: 10.1007/s40265-017-0768-3 EDN: SWSEZC
  92. Asai J. What is new in the histogenesis of granulomatous skin diseases? J Dermatol. 2017;44(3):297–303. doi: 10.1111/1346-8138.13662
  93. Cruz SA, Stein SL. The clinical presentation and comorbidities associated with granuloma annulare in the pediatric population: A retrospective study. Skinmed. 2022;20(1):24–28.
  94. Joshi TP, Chen V, Dong JL, et al. Atopic comorbidities associated with granuloma annulare: A case-control study in the all of us database. J Am Acad Dermatol. 2023;89(1):145–146. doi: 10.1016/j.jaad.2023.02.012 EDN: AUTJGY
  95. Song EJ, Bezecny J, Farrer S. Recalcitrant generalized granuloma annulare treated successfully with dupilumab. JAAD Case Rep. 2020;7:1–2. doi: 10.1016/j.jdcr.2020.10.021 EDN: JWVQFW
  96. Song X, Chen Z, Zhao Z, Wang A. Treatment of generalized granuloma annulare with dupilumab. J Dermatolog Treat. 2023;34(1):2186158. doi: 10.1080/09546634.2023.2186158 EDN: UQLGFA
  97. Paganini C, Talamonti M, Campione E, et al. Letter in response to the case report: “Recalcitrant generalized granuloma annulare treated successfully with dupilumab”. JAAD Case Rep. 2023;39:152–154. doi: 10.1016/j.jdcr.2023.07.018
  98. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399. doi: 10.1111/bjd.14164
  99. Blum S, Altman D. Treatment of generalized granuloma annulare with apremilast: A report of 2 cases. JAAD Case Rep. 2019;5(11):976–978. doi: 10.1016/j.jdcr.2019.09.015
  100. Joshi TP, Tschen J. Apremilast in the management of disseminated granuloma annulare. Cureus. 2021;13(5):e14918. doi: 10.7759/cureus.14918 EDN: TIESSK
  101. Hansel K, Biondi F, Bianchi L, et al. Generalized granuloma annulare successfully treated with apremilast: Report of two cases and literature review. Clin Exp Dermatol. 2021;46(8):1603–1606. doi: 10.1111/ced.14806
  102. Bishnoi A, Raj D, Vinay K, Dogra S. Refractory generalized granuloma annulare treated with oral apremilast. JAMA Dermatol. 2019;155(11):1318–1320. doi: 10.1001/jamadermatol.2019.2130
  103. Chen A, Truong AK, Worswick S. The role of biologics in the treatment of chronic granuloma annulare. Int J Dermatol. 2019;58(5):622–626. doi: 10.1111/ijd.14350
  104. Horoub YA, Walker K. Improvement of generalized granuloma annulare with adalimumab: A case report. SAGE Open Med Case Rep. 2024;12:2050313X241231427. doi: 10.1177/2050313х241231427 EDN: IRQQLN
  105. Antoñanzas J, Rodríguez-Garijo N, Tomás-Velázquez A, et al. Treatment of recalcitrant reactive granulomatous dermatitis: Granuloma annulare subtype with etanercept. Dermatol Ther. 2020;33(6):e14081. doi: 10.1111/dth.14081 EDN: SPDOKC
  106. Bürgler C, Vinay K, Häfliger S, et al. Infliximab reduces activated myeloid dendritic cells, different macrophage subsets and CXCR3-positive cells in granuloma annulare. J Dermatol. 2019;46(9):808–811. doi: 10.1111/1346-8138.14981
  107. Ratnarathorn M, Raychaudhuri SP, Naguwa S. Disseminated granuloma annulare: A cutaneous adverse effect of anti-TNF agents. Indian J Dermatol. 2011;56(6):752–754. doi: 10.4103/0019-5154.91847
  108. Awad A, Nirenberg A, Sinclair R. Treatment of generalized granuloma annulare with tildrakizumab. Australas J Dermatol. 2022;63(3):e285–e288. doi: 10.1111/ajd.13858 EDN: PPXKJQ
  109. Song EJ. Tildrakizumab ineffective in generalized granuloma annulare. JAAD Case Rep. 2020;7:3–4. doi: 10.1016/j.jdcr.2020.10.034 EDN: WPXFJM
  110. Berk-Krauss J, Weiner D, Rosenbach M. Results of a treatment algorithm for generalized granuloma annulare. J Am Acad Dermatol. 2024;90(2):377–380. doi: 10.1016/j.jaad.2023.09.050 EDN: GJJBEY

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».